Mark Benson, MD
Cardiovascular Disease · Boston, MANPI 1720306608
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $142 of the $161 with a category attached, or 88.3%. Boehringer Ingelheim accounts for 70.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $95 and has fallen 50.7% since, to $47 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in MA, where the typical reported total is $954.
Across 4 payments — averaging $40.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$114
- Amgen$47
Across 11 payments — averaging $36,094 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$204K
- Amgen$98K
- Novartis$96K
What the payments were for
- Food & beverage$14288%
- Education$1912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $114 |
| Amgen | 2 | $47 |
How this compares
$161 in reported general payments places this provider in the 25th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 82 | $92,544 |
| Praluent PenAlirocumab | 32 | $33,569 |
| Repatha PushtronexEvolocumab | 12 | $6,795 |
| Ezetimibe | 63 | $3,644 |
| Rosuvastatin Calcium | 62 | $1,607 |
| Metoprolol Succinate | 25 | $647 |
| Atorvastatin Calcium | 24 | $427 |
| ClopidogrelClopidogrel Bisulfate | 12 | $150 |
| Sertraline Hcl | 12 | $102 |
| Amlodipine Besylate | 13 | $74 |
| Losartan Potassium | 13 | $52 |
| Lisinopril | 15 | $50 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.